Syntegon reported record financial performance for fiscal year 2025, driven by strong execution of its customer-focused growth strategy across pharmaceutical, biotech, and food markets.

The company posted a 10% year-on-year increase in revenue to €1.75 billion, while order intake rose to €1.86 billion, providing solid visibility for 2026. EBITDA grew 27% to €282 million, with margins expanding to 16.1%, supported by higher volumes in high-margin segments, operational efficiencies, and improved project execution.

Free cash flow surged 51% to €196 million, backed by strong earnings growth and disciplined capital management.

CEO Torsten Türling said the company made “significant progress” in its transformation into a strategic lifecycle partner, adding that Syntegon is now positioned on a “strong, scalable value creation platform” for long-term growth.

The company continued to invest in capacity expansion and innovation during the year, including establishing a Business Excellence Center in Stuttgart and a new pharma solid dosage facility in Fellbach, Germany.

It also allocated €56 million to research and development for next-generation line solutions.

Syntegon’s Pharma business remained a key growth driver, with sales rising 22% year-on-year, supported by increasing demand for biologics and advanced injectable therapies. The acquisition of Telstar further strengthened its end-to-end pharmaceutical offerings, delivering ahead-of-plan integration results in its first year.

The Food segment also saw strong traction, led by customer adoption of the SVX product platform, while the service business maintained steady growth amid rising demand for performance upgrades and advanced service solutions.

A major highlight of the year was the launch of SynTiso, positioned as the world’s first gloveless high-speed filling line for liquid pharmaceuticals, aimed at reducing contamination risks and improving manufacturing efficiency. The solution has already generated significant market interest and initial orders from large pharmaceutical companies.

CFO Eros Carletti noted that the company delivered “meaningful improvements” across all key financial metrics while maintaining disciplined investment and capital allocation.